INVESTOR<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t\t\t

\n\t\t\t\t\t

\n\t\t\t

\n\t\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t

Company Information<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t

\n\t\t\t

\n\t\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t

4DMedical is an Australian-based medical technology company, commercialising four-dimensional lung imaging solutions.<\/h3>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t4DMedical was incorporated in 2012 to acquire imaging platform, XV Technology\u2122, and associated intellectual property, from Monash University where it was originally conceived in 2005 and developed by CEO, Andreas Fouras, and his former research group.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t4DMedical\u2019s XV Technology\u2122 is the first FDA cleared respiratory imaging solution that utilises mathematical models and algorithms to convert sequences of X-ray images into four-dimensional quantitative data. XV Technology\u2122 is the result of over 15 years of development and published preclinical and clinical studies. The technology has been extensively patented, with core patents granted in key jurisdictions including the United States and Australia.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t\t\t\t\t4DMedical considers its market opportunity to be supplementing or replacing existing respiratory diagnostic modalities. In 2019, more than US$31 billion was spent on respiratory diagnostics across more than 377 million procedures globally.\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

\n\t\t\t\t\t\t

\n\t\t\t\t\t

\n\t\t\t

\n\t\t\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t

Announcements<\/h2>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t

\n\t\t\t\t

\n\t\t\t\t\t